The Fly | NTRA

Natera

· NTRA

Dashboard

Financials

Ratios

Transcripts

Valuation

Yesterday

Natera price target raised by $5 at BTIG, here's why

NTRA

Yesterday, 1:00 PM

Natera announces Signatera receives regulatory approval in Japan

NTRA

Yesterday, 5:03 AM

Natera price target lowered by $20 at Barclays, here's why

NTRA

Yesterday, 4:50 AM

Tuesday

NCCN recommends ctDNA-MRD testing using Signatera technology

NTRA

Jun 23, 5:21 PM

Natera price target raised by $20 at BTIG, here's why

NTRA

Jun 23, 5:19 PM

Monday

NCCN guidelines may be meaningful catalyst for Natera, says Leerink

NTRA

Jun 22, 11:45 AM

Over a week ago

Natera resumed with an Outperform at RBC Capital

NTRA

Jun 11, 4:15 PM

Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls

+12

Jun 5, 9:36 AM

Natera initiated with neutral view at Goldman Sachs, here's why

NTRA

Jun 5, 4:34 AM

Natera, CytoDyn collaborate to advance ctDNA-guided development

Jun 4, 8:13 AM

Natera appoints Lynch, Rubin to board of directors

NTRA

Jun 3, 8:10 AM

Natera assumed with an Outperform at Wolfe Research

NTRA

Jun 1, 4:28 PM

CareDx denied request to Supreme Court to revive Natera award

Jun 1, 9:37 AM

Natera announces collaboration with Diakonos Oncology for Signatera in RM

NTRA

May 29, 6:03 AM

Natera enrolls first patients in SIGNAL-ER 101 study

NTRA

May 28, 6:08 AM

Natera announces expansion into Austin, creating largest sequencing factory

NTRA

May 21, 7:10 AM

Natera announces Expand trial enrolled over 2,000 patients

NTRA

May 20, 7:02 AM

Signatera CDx approved by FDA as companion diagnostic in MIBC

May 15, 12:49 PM

FDA approves Genentech's Tecentriq for adjuvant muscle-invasive bladder cancer

May 15, 12:47 PM

Cathie Wood's ARK Investment buys 17.3K shares of Natera today

NTRA

May 13, 9:34 PM

Natera price target raised by $9 at Piper Sandler, here's why

NTRA

May 12, 6:41 AM

Natera price target raised by $8 at Baird, here's why

NTRA

May 8, 8:50 AM

Natera price target raised by $20 at Evercore ISI

NTRA

May 8, 8:05 AM

Natera price target raised by $5 at Wells Fargo, here's why

NTRA

May 8, 7:41 AM

Natera price target raised by $5 at JPMorgan

NTRA

May 8, 7:36 AM

Proprietary SNP-Based cfDNA Platform: Their core genetic analysis technology provides high accuracy and unique insights across their product portfolio.

Market Leadership in Personalized MRD Testing: Signatera's personalized approach to oncology recurrence monitoring positions them at the forefront of a high-growth segment.

Diversified Portfolio in High-Growth Diagnostics: Presence in NIPT, oncology, and transplant leverages a common technological platform across large, expanding markets.

Reimbursement & Payer Coverage Challenges: Natera's financial performance is highly dependent on securing and maintaining adequate reimbursement from third-party payers for its genetic tests, which can be uncertain and subject to change.

Intense Competitive Landscape: The genetic testing market is highly competitive, with numerous companies offering similar or alternative tests, which could limit Natera's market share, pricing power, and ability to grow.

Evolving Regulatory Environment & Scrutiny: Changes in regulations related to laboratory-developed tests (LDTs), increased FDA oversight, or other new policies could significantly impact Natera's operations, require costly compliance, or restrict test availability.

Charts

Proprietary SNP-Based cfDNA Platform: Their core genetic analysis technology provides high accuracy and unique insights across their product portfolio.

Market Leadership in Personalized MRD Testing: Signatera's personalized approach to oncology recurrence monitoring positions them at the forefront of a high-growth segment.

Diversified Portfolio in High-Growth Diagnostics: Presence in NIPT, oncology, and transplant leverages a common technological platform across large, expanding markets.